In this work, we applied this method to study the interaction of CML-derived cell lines with fibronectin and the effects of the most commonly used tyrosine kinase inhibitors, imatinib (mainly targeting BCR-ABL) and dasatinib (a dual ABL/SRC family kinase inhibitor). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.